2022 HF Guidelines Flashcards
COR for CardioMEMS and two trials
2b for class III HF on max GDMT
CHAMPION-HF & GUIDE-HF
Peak VO2 cutoffs for transplant
<14 mL/kg/min
(<12 if on BB)
Based on GISSI-HF, this drug received a 2b rec for class II-IV HF to reduce mortality and CV hospitalizations
omega-3 polyunsaturated fatty acid (PUFA)
These two classes of diabetes drugs has a COR III:harm in the HF guidelines
Thiazolidinediones
DPP4-inhibitors (saxagliptin)
Mechanism of vericiguat and trial supporting its use in HF guidelines
Oral guanylate cyclase stimulator
VICTORIA
Post-MI 1* prevention ICD indications
-40 days post MI AND
-On good GDMT AND
-Survival >1yr
-LVEF </=35% and class II or III sx OR
-LVEF </=30% and class I symptoms
In genetic arrhythmogenic cardiomyopathies, 1* prevention ICD indication
2a: LVEF <45% if high-risk features present
HF guideline revascularization indications
1-B for surgical revasc w/ LVEF </=35% and suitable anatomy (LM or equivalent)
COR 1 recs for HFpEF
BP management
COR 2a recs for HFpEF
SGLT2i to reduce HHF and CVD
AF management
COR 2b recs for HFpEF
MRAs
ARB
ARNi
COR 3: no benefit recs for HFpEF and trials
PDE5i
(RELAX)
Nitrates
(NEAT-HFpEF)
Dobutamine should be used with caution in pts with this allergy
sulfite
This class of medications increases the toxicity of inotropes (except milrinone)
MAO-Is
This “shock index” suggests CS in HF guidelines
HR/SBP > 1.0
This CPO suggests CS in HF guidelines
[COxMAP]/451 <0 .6
This is the most common comorbidity with HF
HTN (84%)
Class III: harm rec in HF guidelines related to central sleep apnea
adaptive servo-ventilation (increased mortality in 2 RCTs)
